Opaleye Management Inc.'s Form 4 filing
Eton Pharmaceuticals, Inc. (ETON) · filed Sep 12, 2024
- Accession no.
- 0001493152-24-036104
- Filed
- Sep 12, 2024
- Trade date
- Sep 10-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $504.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Opaleye Management Inc.CIK 0001595855 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2024 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +50,000 | $4.65 | +$232,500 | 2,660,000 | Indirect | |
| Sep 10, 2024 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +7,500 | $4.65 | +$34,875 | 70,000 | Indirect | |
| Sep 11, 2024 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +45,000 | $4.75 | +$213,750 | 2,705,000 | Indirect | |
| Sep 11, 2024 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +5,000 | $4.75 | +$23,750 | 75,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.